Brief: Rafael Pharmaceuticals Enrolls More Than 75% Of Patients Needed For Pivotal Phase 3 TrialOf CPI-613 For Patients With Metastatic Pancreatic Cancer
24/03/2020 13:20
March 24 (Reuters) - Rafael Holdings Inc RFL.N :
* RAFAEL PHARMACEUTICALS ENROLLS MORE THAN 75% OF PATIENTS
NEEDED
FOR PIVOTAL PHASE 3 TRIAL (AVENGER 500) OF CPI-613®️
(DEVIMISTAT) FOR PATIENTS WITH METASTATIC PANCREATIC CANCER
Source text for Eikon: ID:nGNX1QHrPF
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million